GLP-1s and Sleep Apnea: The Data That Could Get You Off CPAP

If you snore loud enough to wake your wife, use a CPAP machine, or just wake up exhausted despite "sleeping" eight hours — this might be the most relevant GLP-1 research you'll read this year.

Obstructive sleep apnea (OSA) affects an estimated 30 million American men. The standard treatment — a CPAP machine strapped to your face every night — has a compliance rate that's notoriously poor. Most men hate it. Many stop using it within the first year.

Now the data is piling up: GLP-1 medications may offer a fundamentally different path.

The Data That Changed the Conversation

In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first GLP-1-class drug to receive this indication. The approval was based on the SURMOUNT-OSA trial program:

That number is dramatic. Up to 43% of tirzepatide patients achieved an AHI below 5 — effectively resolving their sleep apnea entirely. For context, CPAP typically reduces AHI by about 60–80% but only works when you're wearing it. GLP-1s work 24/7 because the mechanism is weight loss and metabolic improvement, not mechanical airway splinting.

The 93,000-Patient Confirmation

A study published in JAMA Network Open (December 2025) analyzed over 93,000 patients with obesity, type 2 diabetes, and sleep apnea. Compared to SGLT2 inhibitors, those taking GLP-1 medications were:

• 8% less likely to need a CPAP machine
• 32% less likely to die from any cause
• 10% less likely to be hospitalized

Those all-cause mortality numbers are what got cardiologists' attention. The benefit appears to extend well beyond airway mechanics.

May 2026 Update: Not Everyone Responds Equally

Data presented at ATS 2026 (American Thoracic Society) identified, for the first time, a "strong response" subtype — patients who experienced nearly twice the improvement in sleep apnea compared to the average treatment group. This is the first identification of a predictable strong-responder phenotype for GLP-1 treatment of OSA.

The implication: genetic and metabolic profiling could eventually tell you whether GLP-1 therapy will significantly improve your sleep apnea before you start treatment.

Why Men Are Disproportionately Affected

Sleep apnea hits men harder. Male anatomy — thicker necks, more upper-body fat distribution, and testosterone-influenced airway tissue — creates higher OSA prevalence. Men are 2–3x more likely to have clinically significant sleep apnea than women. The combination of visceral obesity and OSA creates a metabolic cascade: poor sleep → elevated cortisol → insulin resistance → more visceral fat → worse sleep apnea.

GLP-1s attack this cycle at the root: reduce visceral fat, improve insulin sensitivity, and the airway improvements follow.

CPAP vs. GLP-1: Not Either/Or

Important nuance: stopping CPAP requires a repeat sleep study documenting AHI below the treatment threshold. Premature CPAP discontinuation carries real cardiovascular and accident risk. The realistic path for most men:

1. Start GLP-1 therapy while continuing CPAP
2. Lose significant weight over 6–12 months
3. Get a follow-up sleep study
4. If AHI is resolved or significantly reduced, discuss CPAP adjustment with your sleep specialist

Some men will be able to ditch the CPAP entirely. Others will reduce their pressure settings significantly. Either way, it's better sleep and better health.

Getting Started

If you have sleep apnea and obesity, you may qualify for GLP-1 therapy through one of the providers below. Some, like BiltRx, offer full men's health platforms covering GLP-1s alongside TRT and ED treatment — relevant if sleep apnea is part of a broader hormonal picture.